Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database.

IF 2 Q2 ECONOMICS

PharmacoEconomics Open Pub Date : 2025-03-19 DOI:10.1007/s41669-025-00565-3

Pavo Marijic, Roman Kliemt, Martin Krammer, Nikolaus Kolb, Theo Last, Andreas Ambrosch, Santiago Ewig, Rembert Koczulla, Jörg Schelling, Claus Vogelmeier, Maria Waize, Manuela Stierl, Maria João Fonseca, Sara Pedron, Alen Marijam

{"title":"Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database.","authors":"Pavo Marijic, Roman Kliemt, Martin Krammer, Nikolaus Kolb, Theo Last, Andreas Ambrosch, Santiago Ewig, Rembert Koczulla, Jörg Schelling, Claus Vogelmeier, Maria Waize, Manuela Stierl, Maria João Fonseca, Sara Pedron, Alen Marijam","doi":"10.1007/s41669-025-00565-3","DOIUrl":null,"url":null,"abstract":"Background: Respiratory syncytial virus (RSV) infections pose health and economic burdens to adults. Using claims data, we estimated RSV-associated costs, healthcare resource utilization (HCRU), and complication rates from patients of a nationwide German health insurance database.Methods: We analyzed confirmed RSV, RSV-possible, and acute respiratory infection (ARI) cohorts, plus 1:1 matched control cohorts of individuals ≥ 18 years from 2010 to 2019. Matching was performed separately for patients 18-49, 50-59, and ≥ 60 years. Medical costs, HCRU, and sick leave were assessed for inpatients and outpatients. Complications were compared between cases and controls, and logistic regression assessed odds ratios (ORs) for risk.Results: Altogether, 2668 confirmed RSV index episodes occurred. In ≥ 60-year-olds, 862 episodes incurred mean excess costs of €3773 (95% confidence interval [CI]: €2956-€4591) per episode during the index quarter and €3286 (95% CI: €1841-€4732) in the following four quarters. Mean costs were €5553 per episode for inpatients and €116 for outpatients. In ≥ 60-year-olds, risk for congestive heart failure hospitalization (OR 2.3; 95% CI: 1.4-3.8), exacerbation of asthma (OR 6.0; 95% CI: 1.7-20.9), and chronic obstructive pulmonary disease (OR 3.9; 95% CI: 2.6-5.8) were higher for confirmed RSV than controls. In younger groups, costs, HCRU, and complications were also higher in cases than controls. The complication frequencies increased with age. RSV-possible episodes incurred mean excess costs of €615 (95% CI: €605-€626) during the index quarter and €610 (95% CI: €583-€637) during the following four quarters, while in the ARI cohort, the excess costs were €1003 (95% CI: €991-€1015) during the index quarter and €1003 (95% CI: €973-€1032) in the following four quarters. For all three cohorts, individuals who had comorbidities, were immunocompromised, or living in long-term care facilities incurred higher costs.Conclusions: Confirmed RSV is associated with high excess costs - especially in hospital settings - and HCRU. Complication risk increased with RSV presence.","PeriodicalId":19770,"journal":{"name":"PharmacoEconomics Open","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41669-025-00565-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Respiratory syncytial virus (RSV) infections pose health and economic burdens to adults. Using claims data, we estimated RSV-associated costs, healthcare resource utilization (HCRU), and complication rates from patients of a nationwide German health insurance database.

Methods: We analyzed confirmed RSV, RSV-possible, and acute respiratory infection (ARI) cohorts, plus 1:1 matched control cohorts of individuals ≥ 18 years from 2010 to 2019. Matching was performed separately for patients 18-49, 50-59, and ≥ 60 years. Medical costs, HCRU, and sick leave were assessed for inpatients and outpatients. Complications were compared between cases and controls, and logistic regression assessed odds ratios (ORs) for risk.

Results: Altogether, 2668 confirmed RSV index episodes occurred. In ≥ 60-year-olds, 862 episodes incurred mean excess costs of €3773 (95% confidence interval [CI]: €2956-€4591) per episode during the index quarter and €3286 (95% CI: €1841-€4732) in the following four quarters. Mean costs were €5553 per episode for inpatients and €116 for outpatients. In ≥ 60-year-olds, risk for congestive heart failure hospitalization (OR 2.3; 95% CI: 1.4-3.8), exacerbation of asthma (OR 6.0; 95% CI: 1.7-20.9), and chronic obstructive pulmonary disease (OR 3.9; 95% CI: 2.6-5.8) were higher for confirmed RSV than controls. In younger groups, costs, HCRU, and complications were also higher in cases than controls. The complication frequencies increased with age. RSV-possible episodes incurred mean excess costs of €615 (95% CI: €605-€626) during the index quarter and €610 (95% CI: €583-€637) during the following four quarters, while in the ARI cohort, the excess costs were €1003 (95% CI: €991-€1015) during the index quarter and €1003 (95% CI: €973-€1032) in the following four quarters. For all three cohorts, individuals who had comorbidities, were immunocompromised, or living in long-term care facilities incurred higher costs.

Conclusions: Confirmed RSV is associated with high excess costs - especially in hospital settings - and HCRU. Complication risk increased with RSV presence.

查看原文本刊更多论文

成人呼吸道合胞病毒和急性呼吸道感染的费用和并发症：德国索赔数据库的分析。

背景：呼吸道合胞病毒（RSV）感染给成年人带来健康和经济负担。利用索赔数据，我们估计了来自德国全国健康保险数据库患者的rsv相关成本、医疗资源利用率（HCRU）和并发症发生率。方法：我们分析了确诊的RSV、可能的RSV和急性呼吸道感染（ARI）队列，以及2010年至2019年年龄≥18岁个体的1:1匹配对照队列。分别对18-49岁、50-59岁和≥60岁的患者进行匹配。对住院病人和门诊病人的医疗费用、HCRU和病假进行了评估。比较病例和对照组之间的并发症，并用logistic回归评估风险的优势比（or）。结果：共发生2668例确诊RSV指数发作。在60岁以上的人群中，在指标季度，862次发作的平均超额成本为每集3773欧元（95%置信区间[CI]: 2956欧元至4591欧元），在接下来的四个季度中为3286欧元（95%置信区间：1841欧元至4732欧元）。住院患者的平均费用为每集5553欧元，门诊患者为116欧元。≥60岁人群充血性心力衰竭住院风险(OR 2.3；95% CI: 1.4-3.8)，哮喘加重(OR 6.0；95% CI: 1.7-20.9)和慢性阻塞性肺疾病(OR 3.9；95% CI: 2.6-5.8)确诊RSV患者高于对照组。在较年轻的组中，病例的成本、HCRU和并发症也高于对照组。并发症发生率随年龄增加而增加。rsv可能发生的事件在指数季度平均额外成本为615欧元（95% CI：€605-€626），在接下来的四个季度为610欧元（95% CI：€583-€637），而在ARI队列中，指数季度的额外成本为1003欧元（95% CI：€991-€1015），接下来的四个季度为1003欧元（95% CI：€973-€1032）。在所有三个队列中，患有合并症、免疫功能低下或生活在长期护理机构的个体花费更高。结论：确诊的呼吸道合胞病毒与高额外费用（特别是在医院环境中）和HCRU相关。RSV的存在增加了并发症的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PharmacoEconomics Open Multiple-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： PharmacoEconomics - Open focuses on applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. The journal includes, but is not limited to, the following research areas:Economic analysis of healthcare interventionsHealth outcomes researchCost-of-illness studiesQuality-of-life studiesAdditional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in PharmacoEconomics -Open may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.